Heart disease remains the top cause of death in the United States, yet many individuals with underlying heart conditions are unaware of their risks. Cleerly, a startup focused on cardiovascular imaging, aims to change this by using AI to analyze CT heart scans for early signs of coronary artery disease, similar to how cancer screenings detect abnormalities.
Founded by cardiologist James Min in 2017, Cleerly is conducting a multi-year clinical trial to prove that its AI screening method is more effective than traditional non-invasive approaches like blood pressure or cholesterol checks. If successful, it could lead to widespread screening, providing significant benefits for both individuals and the healthcare system.
With investor interest soaring, Cleerly recently raised $106 million in a Series C extension. This follows a $223 million round and will fund clinical trials and future growth. Already FDA-approved for diagnosing symptomatic patients, Cleerly’s technology could transform heart disease detection, offering a less invasive alternative to stress tests and angiograms. With growing acceptance from insurers, Cleerly’s AI-based approach is poised for rapid expansion.
